Watch Ticker

Purple Biotech Ltd. American Depositary Shares

Go to Purple Biotech Ltd. American Depositary Shares Website

$2.15

-0.11 (-4.87%)

Live

Previous Close

$2.15

Day Range

$2.1435 - $2.305

Previous Day Range

$2.17 - $2.325

Market Cap

$6.0 million USD

Day Vol.

38038

Previous Day Vol.

24651

Currency

USD

Primary Exchange

Nasdaq

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Gil Efron - Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech reported significant progress in its oncology pipeline, including promising Phase 2 results for CM24 in pancreatic cancer, advancements in the CAPTN-3 tri-specific antibody platform, and initiation of a Phase 2 study for NT219 in head and neck cancer.

Related tickers: PPBT.

Read Full Article

N/A - Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech is advancing its novel agent NT219 into a Phase 2 study in combination with pembrolizumab or cetuximab for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study aims to address the significant unmet medical need in this patient population.

Related tickers: PPBT.

Read Full Article

Trending Tickers

Please sign in to view